Solventum (NYSE:SOLV) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a research report released on Saturday morning.

Other research analysts have also issued reports about the stock. UBS Group boosted their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Piper Sandler raised their target price on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price target on Solventum in a report on Thursday, August 6th. BMO Capital Markets initiated coverage on Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price target on the stock. Finally, Weiss Ratings upgraded Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.64.

Solventum Trading Up 1.8%

NYSE SOLV opened at $91.22 on Friday. Solventum has a 12 month low of $62.38 and a 12 month high of $91.51. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The stock has a 50 day moving average of $81.20 and a 200-day moving average of $75.14. The company has a market cap of $15.53 billion, a PE ratio of 11.15, a PEG ratio of 1.15 and a beta of 0.60.

Solventum (NYSE:SOLV) last issued its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the company earned $1.69 earnings per share. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts anticipate that Solventum will post 7.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Solventum

Institutional investors have recently added to or reduced their stakes in the stock. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in shares of Solventum during the 2nd quarter valued at about $150,066,000. US Bancorp DE increased its holdings in Solventum by 4.6% in the fourth quarter. US Bancorp DE now owns 444,540 shares of the company’s stock worth $35,225,000 after purchasing an additional 19,400 shares in the last quarter. Davis Selected Advisers increased its holdings in Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares in the last quarter. SG Americas Securities LLC lifted its stake in Solventum by 38.4% in the first quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock valued at $8,467,000 after buying an additional 35,982 shares during the period. Finally, Bank of America Corp DE lifted its stake in Solventum by 0.6% in the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after buying an additional 9,083 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.